Ludwig Institute for Cancer Research Limited

Creative Biomolecules, Inc.

The University of Tokyo

Takeda Pharmaceutical Company Limited

Japanese Foundation for Cancer Research

Hidenori Ichijo

Kohei Miyazono

Ulf G Hellman

Christer Wernstedt

Lars Ronnstrand

Kuber T Sampath

Carl-Henrik Heldin

Tetsuo Nagano

Hirotatsu Kojima

Takayoshi Okabe

Takao Fujisawa

Tsunehiko Higuchi

Masae Saitoh

Kengo Homma

Norio Shiibata

Hideki Nishitoh

Carl-Hendrik Heldin

Naomi Tsuburaya

Seiichi Nakamura

Kohsuke Takeda

Hidehiko Nakagawa

Shin-Ichi Ikeda

Manabu Shimonishi

A compound represented by the following formula (1) is provided: wherein X represents a sulfur atom or &#x2014;CH&#x2550;CH&#x2014;; Ato Aeach independently represent a carbon atom or a nitrogen atom, and at least one of Ato Ais a nitrogen atom; Rrepresents any one of a 1,2,3,4-tetrahydroquinolyl group (or a 3,4-dihydro-1(2H)-quinolyl group), a 3,4-dihydro-4,4-dimethyl-1(2H)-quinolyl group, a 2,3,4,5-tetrahydro-1H-1-benzazepinyl group, or a substituent represented by the following formula (2): wherein Rrepresents a 2,3,4-trifluorophenyl group, a 4-iodophenyl group, a 2,3-difluorophenyl group, a 3,5-difluorophenyl group, a 5-fluoro-2-methylphenyl group, a 3-pentafluorosulfanylphenyl group, a 2,6-dimethylphenyl group, a 4-benzyloxyphenyl group, a 3,5-bis(trifluoromethyl)biphenyl group, a 4-tert-butylphenyl group, a 3-methoxyphenyl group, an unsubstituted or substituted pyridyl group, or an unsubstituted or substituted naphthyl group; Rrepresents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group optionally containing an oxygen atom and/or a double bond, or an unsubstituted or substituted aromatic lower alkyl group; Rrepresents a hydrogen atom, a lower alkyl group, a lower acyl group, or an unsubstituted or substituted aromatic lower alkyl group; and Rrepresents a hydrogen atom, or Rand Rmay bind to each other to form a ring.

Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof

The present invention provides a partial peptide comprising the functional domain of a protein comprising an amino acid sequence which is the same or substantially the same as an amino acid sequence represented by SEQ ID NO:2 or SEQ ID NO: 4; a screening method and a kit therefor for a substance which regulates ASK1 activation, or a prophylactic or therapeutic substance for diseases associated with apoptosis or inflammation, which comprises using the protein or the partial peptide or a cell which produces the same, and optionally ASK1 or a partial peptide thereof or a cell which produces the same; and an agent for regulating apoptosis or inflammatory cytokine production, or a prophylactic or therapeutic agent for diseases associated with apoptosis or inflammation, which comprises a substance for regulating an activity of a protein comprising an amino acid sequence which is the same or substantially the same as an amino acid sequence represented by SEQ ID NO:2 or SEQ ID NO: 4.

Apoptosis-associated protein and use thereof

An object of the present invention is to provide a protein which induces apoptosis, a base sequence encoding the protein, and an agent for use in the treatment of malignant tumors. The present invention is a protein (ASK1) which has protein kinase activity and enhances SEK1 kinase activity and/or MKK3 kinase activity, or a derivative thereof. Malignant tumors can be treated using the protein according to the present invention or the base sequence encoding the protein.

Apoptosis-inducing protein and gene encoding the same

Recombinant TGF-.beta. type I receptor variants having differentially

Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features, and various other data characterizing morphogen cell surface receptors, particularly OP-1-binding cell surface receptors, e.g., ALK-1; (2) methods for producing receptor proteins, including fragments thereof, using recombinant DNA technology; (3) methods for identifying novel morphogen receptors and their encoding DNAs; (4) methods for identifying compounds capable of modulating endogenous morphogen receptor levels; and (5) methods and compositions for identifying and producing morphogen analogs useful in the design of morphogen agonists and antagonists for therapeutic, diagnostic, and experimental uses.

Method for identifying an OP-1 analog which binds an ALK-1 receptor

A novel gene, DD-10, and its encoded polypeptide chain, DD-10, expressed during early onset of morphogen-induced mammalian tissue morphogenesis, now has been discovered. Accordingly, the invention identifies a new gene which is a novel biological marker of cell differentiation and tissue morphogenesis, particularly of chondroblast or osteoblast cell differentiation and bone tissue morphogenesis. Disclosed are: (a) methods and compositions for screening for and producing morphogen analogs; (b) novel morphogen analogs; (c) downstream inducers of morphogenesis; (d) a novel marker for evaluating morphogen or morphogen analog dosing; and (e) therapeutic methods and compositions using these analogs and/or downstream inducers.

Morphogen-responsive signal transducer and methods of use thereof

The invention relates to a family of substantially pure, receptor like TGF-.beta.1 binding glycoproteins. These molecules are characterized by molecular masses of 160 kd, 70-80 kd, and 30-40 kd as determined by SDS-PAGE, and the ability to bind the TGF-.beta.1 molecule. This family of molecules is useful in identifying and/or quantifying TGF-.beta.1 in a sample, as well as inhibiting its effect on cells. Also described are nucleic acid sequences which code for the protein monomer making up the molecules.

Isolated nucleic acid encoding receptor-like TGF-.beta.1 binding protein

Substantially pure receptor like TFG-.beta.1 binding molecules

The invention relates to a family of substantially pure, receptor like TGF-.beta.1 binding glycoproteins. These molecules are characterized by molecular masses of 160 kd, 70-80 kd, and 30-40 kd as determined by SDS-PAGE, and the ability to bind the TGF-.beta.1 molecule. This family of molecules is useful in identifying and/or quantifying TGF-.beta.1 in a sample, as well as inhibiting its effect on cells.

Substantially pure receptor like TGF-.beta. 1 binding molecules and uses

Growing community of inventors

Tokyo, Japan

Hidenori Ichijo